Synthesis
January 8, 2020
Robert B. Kargbo, Alexander M. Sherwood, Poncho Meisenheimer et al.
31 citations
Described herein is an improved synthesis of 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate (psilocybin). The protocol outlines: synthesis of multigram quantities of psilocybin, identification of critical in-process parameters, and isolation of psilocybin without the use of chromatography, TLC, or aqueous workup. The synthesis furnishes psilocybin in five steps in 23% overall...
Psychiatry Research
January 2, 2020
Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas et al.
234 citations
The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges' gs=1.16 to 1.47) and statistically significant....
Journal of Contextual Behavioral Science
2020
Jordan Sloshower, Jeffrey Guss, Robert Krause et al.
168 citations
Abstract Psychedelic-assisted therapy is based on the premise that psychedelic substances can act as catalysts or adjuncts to psychotherapeutic processes. Recent clinical trials involving psychedelic-assisted therapy have generally employed a similar three-part structure consisting of preparation, support during the dosing sessions, and subsequent “integration.” However, the content of these...
Common Library Network (Der Gemeinsame Bibliotheksverbund)
2020
Janis Fricke
In der gegenwärtigen Arbeit wurden die Strukturvielfalt und die genetischen und enzymatischen Grundlagen der Indolalkaloidbiosynthese in Basidiomyceten in Psilocybe spp. untersucht. Durch in silico-Analysen und heterologe Expression ist es gelungen, die Biosynthese des Psilocybins aufzuklären, die verantwortlichen Gene zu identifizieren und die resultierenden Enzyme biochemisch und...
medRxiv
December 12, 2019
Ron Shore, Paul Ioudovski, Craig Goldie et al.
8 citations
preprint
Abstract We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psilocybin is a naturally-occurring tryptophan derivative found in species of mushroom with psycho-active properties. From 2022 records identified by database searching, 40 publications were included in the qualitative synthesis from which we identified 9...
ChemBioChem
December 4, 2019
Richard Demmler, Janis Fricke, Sebastian Dörner et al.
31 citations
Abstract Psychotropic Psilocybe mushrooms biosynthesize their principal natural product psilocybin in five steps, among them a phosphotransfer and two methyltransfer reactions, which consume one equivalent of 5′‐adenosine triphosphate (ATP) and two equivalents of S ‐adenosyl‐ l ‐methionine (SAM). This short but co‐substrate‐intensive pathway requires nucleoside cofactor salvage to maintain high...
Australian & New Zealand Journal of Psychiatry
November 22, 2019
Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al.
19 citations
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...
Chemistry - A European Journal
November 14, 2019
Felix Blei, Sebastian Dörner, Janis Fricke et al.
80 citations
Abstract The psychotropic effects of Psilocybe “magic” mushrooms are caused by the l ‐tryptophan‐derived alkaloid psilocybin. Despite their significance, the secondary metabolome of these fungi is poorly understood in general. Our analysis of four Psilocybe species identified harmane, harmine, and a range of other l ‐tryptophan‐derived β‐carbolines as their natural products, which was confirmed...
Psychopharmacology
November 1, 2019
Suzanne L. Russ, R L Carhart-Harris, Geoffrey Maruyama et al.
75 citations
Recent research demonstrated the potential of psychedelic drugs as treatment for depression and death-related anxiety and as an enhancement for well-being. While generally positive, responses to psychedelic drugs can vary according to traits, setting, and mental state (set) before and during ingestion. Most earlier models explain minimal response variation, primarily related to dosage and...
Scientific Reports
October 24, 2019
Lukasz Smigielski, Michael Kometer, Milan Scheidegger et al.
174 citations
Meditation and psychedelics have played key roles in humankind's search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (n = 39) during a...